LGD-4033 (Ligandrol)
Price on application
LGD-4033 (Ligandrol) is an orally active, non-steroidal SARM that binds to androgen receptors with high affinity and selectivity. It is one of the most widely researched SARMs for its potent anabolic effects on muscle and bone tissue with minimal impact on the prostate.
Research Profile
LGD-4033 (Ligandrol) was originally developed by Ligand Pharmaceuticals and later licensed to Viking Therapeutics. It binds selectively to androgen receptors in skeletal muscle and bone, activating anabolic pathways that drive protein synthesis, lean muscle hypertrophy, and increased bone mineral density. Clinical trials have demonstrated dose-dependent increases in lean body mass with favorable safety profiles. LGD-4033 does not significantly aromatize, and its tissue-selective mechanism avoids the androgenic side effects commonly associated with anabolic steroids. These properties make it one of the most studied SARMs for applications related to muscle wasting, sarcopenia, and osteoporosis research.
Technical Details
- Chemical Formula
- C14H12F6N2O
- Synonyms
- Ligandrol, VK5211, LGD-4033
- Molecular Weight
- 338.25 g/mol
- CAS Number
- 1165910-22-4
- PubChem ID
- 44137686
- Active Ingredient
- 350mg (10mg per capsule)
- Shelf Life
- 36 months